文献速递抗栓抗凝管理

当代心血管试验中的复合终点:III期试验趋势与监管审评关键问题

Composite Endpoints in Contemporary Cardiovascular Trials: Trends in Phase 3 Trials and Key Issues in Regulatory Review.
PubMed 文献 · Clin Pharmacol Ther · 2026-06-29

该研究对2015-2024年心血管III期试验进行描述性综述,纳入173项设定复合主要终点的试验,并分析日本、美国、欧盟监管机构对复合终点的审评关注。结果显示硬终点仍常见但复合终点事件范围扩大,监管机构一致关注组分临床重要性差异及复合结果可解释性。

要点

  • 复合终点各组分临床重要性不同,需谨慎解读整体结果。
  • 近年复合终点纳入的事件范围有所扩大,硬终点仍常见。
  • 监管审评一致关注组分重要性差异与复合结果可解释性。

核心结论

  • 试验设计与评价中需考虑复合终点各组分的临床重要性差异,并结合单个组分结果谨慎解读复合终点结果。

研究设计与样本

  • 对2015-2024年心血管III期试验发表文献及ClinicalTrials.gov注册信息进行描述性综述,纳入173项设定复合主要终点的试验。
  • 分析日本、美国、欧盟监管机构对心血管新药申请中复合终点的审评意见,涉及慢性心力衰竭、转甲状腺素蛋白淀粉样心肌病及需抗栓治疗的心血管疾病。

主要发现

  • 硬终点如死亡仍常见,但近年来复合终点纳入的事件范围有所增加。
  • 监管机构跨区域一致关注复合终点各组分临床重要性差异及复合结果的可解释性。

临床怎么用

  • 在试验设计中应明确各组分临床重要性,并在评价时结合单个组分结果解读复合终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Interpreting composite endpoints in cardiovascular drug development is a key challenge, particularly when events of different clinical relevance are combined into a single primary outcome. Previous reviews noted that conventional composite endpoints may mask clinically meaningful differences at the individual component level and be mainly driven by less clinically important "soft" events, raising concerns about how overall treatment effects should be understood. Despite these concerns, information remains limited on how composite endpoints are used in current cardiovascular drug development programs and how their interpretation influences regulatory decision-making. Thus, we conducted a descriptive review of cardiovascular phase III trial publications and ClinicalTrials.gov registries (2015-2024) that specified a composite primary endpoint and identified 173 trials. Hard endpoints such as death remain common; however, the range of events included in composite endpoints has increased in recent years. The examination of regulatory evaluations of composite endpoints in new drug applications for cardiovascular diseases-including chronic heart failure, transthyretin amyloid cardiomyopathy, and cardiovascular conditions requiring antithrombotic therapy-in Japan, the United States, and the European Union revealed that regulatory agencies consistently raised concerns across regions regarding differences in clinical importance among components and the interpretability of composite results. These findings highlight the need to consider differences in clinical importance among components and carefully interpret the composite endpoint results in the context of individual component outcomes, both in trial design and evaluation.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Sugano H, Narukawa M. Composite Endpoints in Contemporary Cardiovascular Trials: Trends in Phase 3 Trials and Key Issues in Regulatory Review. Clin Pharmacol Ther. 2026. PMID: 42374601. doi:10.1002/cpt.70375

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。